Irinotecan in the treatment of colorectal cancer: clinical overview.
about
UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancerPhase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancerIrinotecan, a key chemotherapeutic drug for metastatic colorectal cancerDeveloping a metagenomic view of xenobiotic metabolismIrinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38Equivalent effect of DNA damage-induced apoptotic cell death or long-term cell cycle arrest on colon carcinoma cell proliferation and tumour growth.A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours.Phase I/II study of S-1 combined with biweekly irinotecan chemotherapy in previously treated advanced non-small cell lung cancer.Effects of methimazole on the elimination of irinotecan.Responsiveness of CPT-11 in respect to hMLH1 and hMSH2 protein expression in the primary colorectal cancer.Phase II study of irinotecan, 5-fluorouracil, and leucovorin in relapsed or metastatic colorectal cancer as first-line therapyThe synthesis of a c(RGDyK) targeted SN38 prodrug with an indolequinone structure for bioreductive drug release.Free energy calculations reveal rotating-ratchet mechanism for DNA supercoil relaxation by topoisomerase IB and its inhibition.Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer.Bevacizumab enhances the therapeutic efficacy of Irinotecan against human head and neck squamous cell carcinoma xenograftsMetastatic colorectal cancer: systemic treatment in the new millennium.Amphiphilic p-sulfonatocalix[4]arene as "drug chaperone" for escorting anticancer drugs.Quantitative determination of irinotecan and the metabolite SN-38 by nanoflow liquid chromatography-tandem mass spectrometry in different regions of multicellular tumor spheroids.Pharmacogenomics: road to anticancer therapeutics nirvana?The influence of gut microbiota on drug metabolism and toxicity.Caspase-mediated pro-apoptotic interaction of panaxadiol and irinotecan in human colorectal cancer cells.Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma.Herbal medicines as adjuvants for cancer therapeutics.Fasting protects against the side effects of irinotecan but preserves its anti-tumor effect in Apc15lox mutant mice.Gut microbiota modulation of chemotherapy efficacy and toxicity.Intracellular-signaling tumor-regression modeling of the pro-apoptotic receptor agonists dulanermin and conatumumab.Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan.Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer.Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumoursThymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer.Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancerCetuximab plus irinotecan in refractory colorectal cancer patients.ABCG2 expression in colorectal adenocarcinomas may predict resistance to irinotecan.UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer.Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study.Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens.Impact of biomarkers on clinical trial risk.Filled carbon nanotubes in biomedical imaging and drug delivery.Resveratrol-3-O-glucuronide and resveratrol-4'-O-glucuronide reduce DNA strand breakage but not apoptosis in Jurkat T cells treated with camptothecin.Enzyme/Prodrug Systems for Cancer Gene Therapy.
P2860
Q24648015-38B703E5-8AFA-4248-9B22-5B8C2F665DA7Q24795149-F90091AA-C293-41E3-9945-4B72CDC668D7Q26775949-8F5A90D8-CF08-4B33-B31E-04489183F5CAQ28273307-0366DA85-6FDD-4B3F-A39F-4E55BA77D641Q33183914-8DD23077-1D20-42E3-B433-48E5CFF1170EQ33223556-B12C582A-8489-49E7-B136-917853E5D992Q33370792-D565B26A-DAE0-441C-B034-D07111B40CDAQ33403083-F3E1B9A4-B714-4909-80E5-536427FC73F4Q33647853-541B0736-19FD-4D0F-AB28-0EE248755134Q33746839-047ED9BC-C3C4-40C6-BD79-8A73F868B345Q33746897-53879DB6-91B0-4ED9-B759-70B581A40845Q33775446-9B654B56-4208-4CA7-9A84-F2E410352D7EQ34032792-8C444814-3B68-4BDC-9C85-43B44F100FB2Q34342186-82176C7B-3A9E-4015-ABE7-1BD1DF8F2256Q35028461-30C8D323-EE21-4580-8D70-F6642A8351E3Q35148795-1C5AFA35-A5FB-4031-B31A-9BECFBF91E8DQ35169522-60023E00-9BED-4EB6-86C0-DCEE4D7BDA1CQ35181116-3F7BFF04-6794-442A-8CD5-53FA9ECA6508Q35551155-DE9203A6-5856-4D19-B366-C08E43D7B76DQ35841503-A07FA8DB-A853-4B9E-83AA-B4093F132912Q35950062-F6B132E2-5A57-4332-896C-9660DB936B28Q36009614-36B01CC0-EDDC-42BF-A788-9FA7E9860477Q36154035-069BC9D9-9572-4E1D-BF37-DCDF0D25440BQ36183857-9ABA0529-F1FC-4E7C-876F-E172BD783718Q36300217-51D48EAD-DB3F-4716-8276-1D18093DC50BQ36366424-3F04CED4-3FB7-4999-A4A1-6F3CA7D39559Q36481670-D783BDFD-FD75-4EB5-B9A7-9CF3D685E086Q36614109-648C7F7E-D164-4B7F-AEB3-5195C72680E3Q36648316-11458E8C-7F23-447A-B78C-F9E63EB815FAQ36695672-2D3C4292-705C-43E2-BDC0-06F920B5E23BQ36695872-B4CDD585-C690-4413-878F-1E74728292AFQ36788445-94B683D1-196D-4052-A7FB-34731CBB1CFBQ37287637-32895F62-E8CF-4B31-99B2-6D9ACAE27D4AQ37402459-5655D5E3-9E7A-47BB-86FB-C45BABF0EBF1Q37441604-08E8DF4D-4A5F-4115-A723-4DBFDFDC2265Q37575709-107F5BAE-D167-490A-B9CC-E345D48095C1Q38148601-1A509BBD-34F4-4EBB-97AE-3D41F9BEEF84Q38272176-ABA47026-F0EC-40C4-A65D-E3346BDA03C6Q38637981-6A6D6411-7882-4903-911A-40D15456EBD4Q39064497-99D3B011-AC7E-44B2-A727-70B386D98FA6
P2860
Irinotecan in the treatment of colorectal cancer: clinical overview.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Irinotecan in the treatment of colorectal cancer: clinical overview.
@ast
Irinotecan in the treatment of colorectal cancer: clinical overview.
@en
type
label
Irinotecan in the treatment of colorectal cancer: clinical overview.
@ast
Irinotecan in the treatment of colorectal cancer: clinical overview.
@en
prefLabel
Irinotecan in the treatment of colorectal cancer: clinical overview.
@ast
Irinotecan in the treatment of colorectal cancer: clinical overview.
@en
P2093
P1476
Irinotecan in the treatment of colorectal cancer: clinical overview.
@en
P2093
P304
P356
10.1200/JCO.2001.19.5.1501
P407
P577
2001-03-01T00:00:00Z